Genetically Modified Bacteria – The Perspective of Application in Prevention, Diagnostics and Therapy

1 Aggarwal N., Breedon A.M.E., Davis C.M., Hwang I.Y., Chang M.W.: Engineering probiotics for therapeutic applications: recent examples and translational outlook. Curr. Opin. Biotechnol. 65, 171–179, doi: 10.1016/j.copbio.2020.02.016 (2020) AggarwalN. BreedonA.M.E. DavisC.M. HwangI.Y. ChangM.W. Engineering probiotics for therapeutic applications: recent examples and translational outlook Curr. Opin. Biotechnol. 65 171 179 10.1016/j.copbio.2020.02.016 2020 32304955 Open DOISearch in Google Scholar

2 Akdis C.A.: Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat. Rev. Immunol. doi: 10.1038/s41577-021-00538-7 (2021) AkdisC.A. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat. Rev. Immunol. 10.1038/s41577-021-00538-7 2021 33846604 Open DOISearch in Google Scholar

3 Andrade J.C., Almeida D., Domingos M., Seabra C.L., Machado D., Freitas A.C., Gomes A.M.: Commensal obligate anaerobic bacteria and health: production, storage, and delivery strategies. Front. Bioeng. Biotechnol. 8, doi:10.3389/fbioe.2020.00550 (2020) AndradeJ.C. AlmeidaD. DomingosM. SeabraC.L. MachadoD. FreitasA.C. GomesA.M. Commensal obligate anaerobic bacteria and health: production, storage, and delivery strategies Front. Bioeng. Biotechnol. 8 10.3389/fbioe.2020.00550 2020 729188332582673 Open DOISearch in Google Scholar

4 Bae H.R., Leung P.S.C., Hodge D.L., Fenimore J.M., Jeon S.M., Thovarai V., Dzutsev A., Welcher A.A., Boedigheimer M., Damore M.A., Choi M.S., Fravell R.A. Trinchieri G., Gershwin M.E., Young H.A.: Multi-omics: differential expression of IFN-γ results in distinctive mechanistic features linking chronic inflammation, gut dysbiosis, and autoimmune diseases. J. Autoimmun. 111, 102436, doi: 10.1016/j.jaut.2020.102436 (2020) BaeH.R. LeungP.S.C. HodgeD.L. FenimoreJ.M. JeonS.M. ThovaraiV. DzutsevA. WelcherA.A. BoedigheimerM. DamoreM.A. ChoiM.S. FravellR.A. TrinchieriG. GershwinM.E. YoungH.A. Multi-omics: differential expression of IFN-γ results in distinctive mechanistic features linking chronic inflammation, gut dysbiosis, and autoimmune diseases J. Autoimmun. 111 102436 10.1016/j.jaut.2020.102436 2020 726672332220507 Open DOISearch in Google Scholar

5 Barra M., Danino T., Garrido D.: Engineered probiotics for detection and treatment of inflammatory intestinal diseases. Front. Bioeng. Biotechnol. 8, 265, doi: 10.3389/fbioe.2020.00265 (2020) BarraM. DaninoT. GarridoD. Engineered probiotics for detection and treatment of inflammatory intestinal diseases Front. Bioeng. Biotechnol. 8 265 10.3389/fbioe.2020.00265 2020 713709232296696 Open DOISearch in Google Scholar

6 Barrientos-Durán A., Fuentes-López A., de Salazar A., Plaza-Díaz J., García F.: Reviewing the composition of vaginal microbiota: inclusion of nutrition and probiotic factors in the maintenance of eubiosis. Nutrients, 12, 419, https://doi.org/10.3390/nu12020419 (2020) Barrientos-DuránA. Fuentes-LópezA. de SalazarA. Plaza-DíazJ. GarcíaF. Reviewing the composition of vaginal microbiota: inclusion of nutrition and probiotic factors in the maintenance of eubiosis Nutrients 12 419 https://doi.org/10.3390/nu12020419 2020 10.3390/nu12020419707115332041107 Search in Google Scholar

7 Bezkorovainy A.: Probiotics: determinants of survival and growth in the gut. Am. J. Clin. Nutr. 73, 399–405, https://doi.org/10.1093/ajcn/73.2.399s (2001) BezkorovainyA. Probiotics: determinants of survival and growth in the gut Am. J. Clin. Nutr. 73 399 405 https://doi.org/10.1093/ajcn/73.2.399s 2001 10.1093/ajcn/73.2.399s11157348 Search in Google Scholar

8 Brüssow H.: Problems with the concept of gut microbiota dysbiosis. Microb. Biotechnol. 13, 423–434, doi:10.1111/1751-7915.13479 (2020) BrüssowH. Problems with the concept of gut microbiota dysbiosis Microb. Biotechnol. 13 423 434 10.1111/1751-7915.13479 2020 701782731448542 Open DOISearch in Google Scholar

9 Chang C.J., Lin T.L., Tsai Y.L., Wu T.R., Lai W.F., Lu C.C., Lai H.C.: Next generation probiotics in disease amelioration. J. Food Drug Anal. 27, 615–622, doi: 10.1016/j.jfda.2018.12.011 (2019) ChangC.J. LinT.L. TsaiY.L. WuT.R. LaiW.F. LuC.C. LaiH.C. Next generation probiotics in disease amelioration J. Food Drug Anal. 27 615 622 10.1016/j.jfda.2018.12.011 2019 31324278 Open DOISearch in Google Scholar

10 Corcoran B.M., Ross R.P., Fitzgerald G.F., Dockery P., Stanton C.: Enhanced survival of GroESL-overproducing Lactobacillus paracasei NFBC 338 under stressful conditions induced by drying. Appl. Environ. Microbiol. 72, 5104–7, doi: 10.1128/AEM.02626-05 (2006) CorcoranB.M. RossR.P. FitzgeraldG.F. DockeryP. StantonC. Enhanced survival of GroESL-overproducing Lactobacillus paracasei NFBC 338 under stressful conditions induced by drying Appl. Environ. Microbiol. 72 5104 7 10.1128/AEM.02626-05 2006 148931916820516 Open DOISearch in Google Scholar

11 Da Silva T.F., Casarotti S.N., de Oliveira G.L.V., Penna A.L.B.: The impact of probiotics, prebiotics, and synbiotics on the biochemical, clinical, and immunological markers, as well as on the gut microbiota of obese hosts. Crit. Rev. Food Sci. Nutr. 61, 337–355, doi: 10.1080/10408398.2020.1733483 (2021) Da SilvaT.F. CasarottiS.N. de OliveiraG.L.V. PennaA.L.B. The impact of probiotics, prebiotics, and synbiotics on the biochemical, clinical, and immunological markers, as well as on the gut microbiota of obese hosts Crit. Rev. Food Sci. Nutr. 61 337 355 10.1080/10408398.2020.1733483 2021 32156153 Open DOISearch in Google Scholar

12 Duong M.T., Qin Y., You S.H., Min J.J.: Bacteria-cancer interactions: bacteria-based cancer therapy. Exp. Mol. Med. 51, 12, 1–15, doi: 10.1038/s12276-019-0297-0 (2019) DuongM.T. QinY. YouS.H. MinJ.J. Bacteria-cancer interactions: bacteria-based cancer therapy Exp. Mol. Med. 51 12 1 15 10.1038/s12276-019-0297-0 2019 690630231827064 Open DOISearch in Google Scholar

13 Eun-Sook L., Eun-Ji S., Young-Do N., So-Young L.: Probiotics in human health and disease: from nutribiotics to pharmabiotics. J. Microbiol. 56, 773–782 doi: 10.1007/s12275-018-8293-y (2018) Eun-SookL. Eun-JiS. Young-DoN. So-YoungL. Probiotics in human health and disease: from nutribiotics to pharmabiotics J. Microbiol. 56 773 782 10.1007/s12275-018-8293-y 2018 30353462 Open DOISearch in Google Scholar

14 Ferreira A.K., Mambelli L.I., Pillai S.Y.: Intervening in disease through genetically-modified bacteria. Best Pract. Res. Clin. Gastroenterol. 31, 693–697 (2017) FerreiraA.K. MambelliL.I. PillaiS.Y. Intervening in disease through genetically-modified bacteria Best Pract. Res. Clin. Gastroenterol. 31 693 697 2017 10.1016/j.bpg.2017.09.01729566913 Search in Google Scholar

15 Gałecka M., Basińska A. M., Bartnicka A. Probiotyki – implikacje w praktyce lekarza rodzinnego. Forum Med. Rodz. 12, 170–182 (2018) GałeckaM. BasińskaA. M. BartnickaA. Probiotyki – implikacje w praktyce lekarza rodzinnego Forum Med. Rodz. 12 170 182 2018 Search in Google Scholar

16 Gardiner G.E., O’Sullivan E., Kelly J., Auty M.A., Fitzgerald G.F., Collins J.K., Ross R.P., Stanton C.: Comparative survival rates of human-derived probiotic Lactobacillus paracasei and L. salivarius strains during heat treatment and spray drying. Appl. Environ. Microbiol. 66, 2605–2612, doi: 10.1128/aem.66.6.2605-2612.2000 (2000) GardinerG.E. O’SullivanE. KellyJ. AutyM.A. FitzgeraldG.F. CollinsJ.K. RossR.P. StantonC. Comparative survival rates of human-derived probiotic Lactobacillus paracasei and L. salivarius strains during heat treatment and spray drying Appl. Environ. Microbiol. 66 2605 2612 10.1128/aem.66.6.2605-2612.2000 2000 11058710831444 Open DOISearch in Google Scholar

17 Giron F., Quigley E.M.M.: Pharmabiotic manipulation of the microbiota in gastrointestinal disorders: a clinical perspective. J. Neurogastroenterol. Motil. 24, 355–366, doi: 10.5056/jnm18004 (2018) GironF. QuigleyE.M.M. Pharmabiotic manipulation of the microbiota in gastrointestinal disorders: a clinical perspective J. Neurogastroenterol. Motil. 24 355 366 10.5056/jnm18004 2018 603466629684976 Open DOISearch in Google Scholar

18 Hwang I.Y., Koh E., Wong A., March J.C., Bentley W.E., Lee Y.S., Chang M.W. Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models. Nat. Commun. 8, 15028 doi: 10.1038/ncomms15028 (2017) HwangI.Y. KohE. WongA. MarchJ.C. BentleyW.E. LeeY.S. ChangM.W. Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models Nat. Commun. 8 15028 10.1038/ncomms15028 2017 539427128398304 Open DOISearch in Google Scholar

19 Jach M., Łoś R., Maj M., Malm A.: Probiotyki – aspekty funkcjonalne i technologiczne. Post. Mikrobiol. 52, 161–170 (2013) JachM. ŁośR. MajM. MalmA. Probiotyki – aspekty funkcjonalne i technologiczne Post. Mikrobiol. 52 161 170 2013 Search in Google Scholar

20 Kali A.: Human microbiome engineering: the future and beyond. J. Clin. Diagn. Res. 9, DE01-4, doi: 10.7860/JCDR/2015/14946.6570 (2015) KaliA. Human microbiome engineering: the future and beyond J. Clin. Diagn. Res. 9 DE01-4 10.7860/JCDR/2015/14946.6570 2015 460623726500908 Open DOISearch in Google Scholar

21 Kang M., Choe D., Kim K., Cho B.K., Cho S.: Synthetic biology approaches in the development of engineered therapeutic microbes. Int. J. Mol. Sci. 21, 8744, doi: 10.3390/ijms21228744 (2020) KangM. ChoeD. KimK. ChoB.K. ChoS. Synthetic biology approaches in the development of engineered therapeutic microbes Int. J. Mol. Sci. 21 8744 10.3390/ijms21228744 2020 769935233228099 Open DOISearch in Google Scholar

22 Kramer M.G., Masner M., Ferreira F.A., Hoffman R.M.: Bacterial therapy of cancer: promises, limitations and insights for future directions. Front. Microbiol. 9, 16 doi: 10.3389/fmicb.2018.00016 (2018) KramerM.G. MasnerM. FerreiraF.A. HoffmanR.M. Bacterial therapy of cancer: promises, limitations and insights for future directions Front. Microbiol. 9 16 10.3389/fmicb.2018.00016 2018 581026129472896 Open DOISearch in Google Scholar

23 Kumar M., Yadav A.K., Verma V., Singh B., Mal G., Nagpal R., Hemalatha R.: Bioengineered probiotics as a new hope for health and diseases: an overview of potential and prospects. Future Microbiol. 11, 585–600 doi: 10.2217/fmb.16.4. (2016) KumarM. YadavA.K. VermaV. SinghB. MalG. NagpalR. HemalathaR. Bioengineered probiotics as a new hope for health and diseases: an overview of potential and prospects Future Microbiol. 11 585 600 10.2217/fmb.16.4 2016 27070955 Open DOISearch in Google Scholar

24 Landry B.P., Tabor J.J. Engineering diagnostic and therapeutic gut bacteria. Microbiol. Spectr. 5, doi: 10.1128/microbiolspec.BAD-0020-2017 (2017) LandryB.P. TaborJ.J. Engineering diagnostic and therapeutic gut bacteria Microbiol. Spectr. 5 10.1128/microbiolspec.BAD-0020-2017 2017 29052539 Open DOISearch in Google Scholar

25 Lee J.W., Chan C.T.Y., Slomovic S., Collins J.J. Next-generation biocontainment systems for engineered organisms. Nat. Chem. Biol. 14, 530–537, doi: 10.1038/s41589-018-0056-x (2018) LeeJ.W. ChanC.T.Y. SlomovicS. CollinsJ.J. Next-generation biocontainment systems for engineered organisms Nat. Chem. Biol. 14 530 537 10.1038/s41589-018-0056-x 2018 29769737 Open DOISearch in Google Scholar

26 Lim D., Song M.: Development of bacteria as diagnostics and therapeutics by genetic engineering. J. Microbiol. 57, 637–643, doi: 10.1007/s12275-019-9105-8 (2019) LimD. SongM. Development of bacteria as diagnostics and therapeutics by genetic engineering J. Microbiol. 57 637 643 10.1007/s12275-019-9105-8 2019 31079333 Open DOISearch in Google Scholar

27 Mazhar S.F., Afzal M., Almatroudi A., Munir S., Ashfaq U.A., Rasool M., Raza H., Munir H.M.W., Rajoka M.S.R., Khurshid M.: The prospects for the therapeutic implications of genetically engineered probiotics. J. Food Qual. article ID 9676452 https://doi.org/10.1155/2020/9676452 (2020) MazharS.F. AfzalM. AlmatroudiA. MunirS. AshfaqU.A. RasoolM. RazaH. MunirH.M.W. RajokaM.S.R. KhurshidM. The prospects for the therapeutic implications of genetically engineered probiotics J. Food Qual. article ID 9676452 https://doi.org/10.1155/2020/9676452 2020 10.1155/2020/9676452 Search in Google Scholar

28 Moloko G.M., Mapitsi S.T.: Probiotic engineering: towards development of robust probiotic strains with enhanced functional properties and for targeted control of enteric pathogens. Gut Pathog. 9, 28, doi: 10.1186/s13099-017-0178-9 (2017) MolokoG.M. MapitsiS.T. Probiotic engineering: towards development of robust probiotic strains with enhanced functional properties and for targeted control of enteric pathogens Gut Pathog. 9 28 10.1186/s13099-017-0178-9 2017 542299528491143 Open DOISearch in Google Scholar

29 Mroczyńska M., Libudzisz Z., Gałęcka M., Szachta P.: Mikroorganizmy jelitowe człowieka i ich aktywność metaboliczna. Prz. Gastroenterol. 4, 218–224 (2016) MroczyńskaM. LibudziszZ. GałęckaM. SzachtaP. Mikroorganizmy jelitowe człowieka i ich aktywność metaboliczna Prz. Gastroenterol. 4 218 224 2016 10.5114/pg.2011.24304 Search in Google Scholar

30 Ozdemir T., Fedorec A.J.H., Danino T., Barnes C.P.: Synthetic biology and engineered live biotherapeutics: toward increasing system complexity. Cell Syst. 7, 5–16, doi: 10.1016/j.cels.2018.06.008 (2018) OzdemirT. FedorecA.J.H. DaninoT. BarnesC.P. Synthetic biology and engineered live biotherapeutics: toward increasing system complexity Cell Syst. 7 5 16 10.1016/j.cels.2018.06.008 2018 30048620 Open DOISearch in Google Scholar

31 Paton A.W, Morona R., Paton J.C. Bioengineered microbes in disease therapy. Trends Mol. Med. 18, 417–425, doi: 10.1016/j.molmed.2012.05.006 (2012) PatonA.W MoronaR. PatonJ.C. Bioengineered microbes in disease therapy Trends Mol. Med. 18 417 425 10.1016/j.molmed.2012.05.006 2012 22721939 Open DOISearch in Google Scholar

32 Pedrolli D.B., Ribeiro N.V., Squizato P.N., de Jesus V.N., Cozetto D.A: Team AQA Unesp at iGEM 2017. Engineering microbial living therapeutics: the synthetic biology toolbox. Trends Biotechnol. 37, 100–115, doi: 10.1016/j.tibtech.2018.09.005 (2019) PedrolliD.B. RibeiroN.V. SquizatoP.N. de JesusV.N. CozettoD.A Team AQA Unesp at iGEM 2017. Engineering microbial living therapeutics: the synthetic biology toolbox Trends Biotechnol. 37 100 115 10.1016/j.tibtech.2018.09.005 2019 30318171 Open DOISearch in Google Scholar

33 Plavec T.V., Berlec A.: Engineering of lactic acid bacteria for delivery of therapeutic proteins and peptides. Appl. Microbiol. Biotechnol. 103, 2053–2066, doi: 10.1007/s00253-019-09628-y (2019) PlavecT.V. BerlecA. Engineering of lactic acid bacteria for delivery of therapeutic proteins and peptides Appl. Microbiol. Biotechnol. 103 2053 2066 10.1007/s00253-019-09628-y 2019 30656391 Open DOISearch in Google Scholar

34 Pongking T., Haonon O., Dangtakot R., Onsurathum S., Jusakul A., Intuyod K., Sangka A., Anutrakulchai S., Cha’on U., Pinlaor S., Pinlaor P.: A combination of monosodium glutamate and high-fat and high-fructose diets increases the risk of kidney injury, gut dysbiosis and host-microbial co-metabolism. PLoS One, 15, 4, e0231237, doi:10.1371/journal.pone.0231237 (2020) PongkingT. HaononO. DangtakotR. OnsurathumS. JusakulA. IntuyodK. SangkaA. AnutrakulchaiS. Cha’onU. PinlaorS. PinlaorP. A combination of monosodium glutamate and high-fat and high-fructose diets increases the risk of kidney injury, gut dysbiosis and host-microbial co-metabolism PLoS One 15 4 e0231237 10.1371/journal.pone.0231237 2020 714166732267892 Open DOISearch in Google Scholar

35 Ropot A.V., Karamzin A.M., Sergeyev O.V.: Cultivation of the next-generation probiotic akkermansia muciniphila, methods of its safe delivery to the intestine, and factors contributing to its growth in vivo. Curr. Microbiol. 77, 8, 1363–1372, doi: 10.1007/s00284-020-01992-7 (2020) RopotA.V. KaramzinA.M. SergeyevO.V. Cultivation of the next-generation probiotic akkermansia muciniphila, methods of its safe delivery to the intestine, and factors contributing to its growth in vivo Curr. Microbiol. 77 8 1363 1372 10.1007/s00284-020-01992-7 2020 32318863 Open DOISearch in Google Scholar

36 Rottinghaus A.G., Amrofell M.B., Moon T.S.: Biosensing in smart engineered probiotics. Biotechnol. J. 15, e1900319, doi: 10.1002/biot.201900319 (2020) RottinghausA.G. AmrofellM.B. MoonT.S. Biosensing in smart engineered probiotics Biotechnol. J. 15 e1900319 10.1002/biot.201900319 2020 730504831860168 Open DOISearch in Google Scholar

37 Ruszkowski J., Szewczyk A., Witkowski J. M.: Przegląd doustnych prebiotyków, probiotyków, synbiotyków i postbiotyków dostępnych na polskim rynku aptecznym. Farm. Pol. 74, 2, 114–122 (2018) RuszkowskiJ. SzewczykA. WitkowskiJ.M. Przegląd doustnych prebiotyków, probiotyków, synbiotyków i postbiotyków dostępnych na polskim rynku aptecznym Farm. Pol. 74 2 114 122 2018 10.32383/farmpol/119464 Search in Google Scholar

38 Sharma R., Gupta D., Mehrotra R., Mago P.: Psychobiotics: the next-generation probiotics for the brain. Curr. Microbiol. 78, 2, 449–463, doi: 10.1007/s00284-020-02289-5 (2021) SharmaR. GuptaD. MehrotraR. MagoP. Psychobiotics: the next-generation probiotics for the brain Curr. Microbiol. 78 2 449 463 10.1007/s00284-020-02289-5 2021 33394083 Open DOISearch in Google Scholar

39 Sheehan V.M., Sleator R.D., Fitzgerald G.F., Hill C.: Heterologous expression of BetL, a betaine uptake system, enhances the stress tolerance of Lactobacillus salivarius UCC118. Appl. Environ. Microbiol. 72, 3, 2170–2177, doi: 10.1128/AEM.72.3.2170-2177.2006 (2006) SheehanV.M. SleatorR.D. FitzgeraldG.F. HillC. Heterologous expression of BetL, a betaine uptake system, enhances the stress tolerance of Lactobacillus salivarius UCC118 Appl. Environ. Microbiol. 72 3 2170 2177 10.1128/AEM.72.3.2170-2177.2006 2006 139318316517668 Open DOISearch in Google Scholar

40 Skrzydło-Radomańska B., Wronecki J.: Czy mikrobiotę jelitową można skutecznie modyfikować? Varia Medica, 3, 1, 18–26 (2019) Skrzydło-RadomańskaB. WroneckiJ. Czy mikrobiotę jelitową można skutecznie modyfikować? Varia Medica 3 1 18 26 2019 Search in Google Scholar

41 Sleator R.D., Hill C.: Rational design of improved pharmabiotics. J. Biomed. Biotechnol. 275287, doi: 10.1155/2009/275287 (2009) SleatorR.D. HillC. Rational design of improved pharmabiotics J. Biomed. Biotechnol. 275287 10.1155/2009/275287 2009 274264719753318 Open DOISearch in Google Scholar

42 Sola-Oladokun B., Culligan E.P., Sleator R.D.: Engineered probiotics: applications and biological containment. Annu. Rev. Food Sci. Technol. 28, 8, 353–370, doi: 10.1146/annurev-food-030216-030256 (2017) Sola-OladokunB. CulliganE.P. SleatorR.D. Engineered probiotics: applications and biological containment Annu. Rev. Food Sci. Technol. 28 8 353 370 10.1146/annurev-food-030216-030256 2017 28125354 Open DOISearch in Google Scholar

43 Tan Y., Shen J., Si T., Ho C.L., Yinqing Li Y., Dai L.: Engineered live biotherapeutics: progress and challenges. Review Biotechnol. J. 15, 10, e2000155, doi: 10.1002/biot.202000155 (2020) TanY. ShenJ. SiT. HoC.L. Yinqing LiY. DaiL. Engineered live biotherapeutics: progress and challenges Review Biotechnol. J. 15 10 e2000155 10.1002/biot.202000155 2020 32770635 Open DOISearch in Google Scholar

44 Thursby E., Juge N.: Introduction to the human gut microbiota. Biochem. J. 474, 1823–1836, doi: https://doi.org/10.1042/BCJ20160510 (2017) ThursbyE. JugeN. Introduction to the human gut microbiota Biochem. J. 474 1823 1836 https://doi.org/10.1042/BCJ20160510 2017 10.1042/BCJ20160510543352928512250 Search in Google Scholar

45 Tyagi P., Tasleem M., Prakash S., Chouhan G.: Intermingling of gut microbiota with brain: exploring the role of probiotics in battle against depressive disorders. Food Res. Int. 137, 109489, doi: 10.1016/j.foodres.2020.109489 (2020) TyagiP. TasleemM. PrakashS. ChouhanG. Intermingling of gut microbiota with brain: exploring the role of probiotics in battle against depressive disorders Food Res. Int. 137 109489 10.1016/j.foodres.2020.109489 2020 33233143 Open DOISearch in Google Scholar

46 Vallianou N., Stratigou T., Christodoulatos G.S., Tsigalou C., Dalamaga M.: Probiotics, prebiotics, synbiotics, postbiotics, and obesity: current evidence, controversies, and perspectives. Curr. Obes. Rep. 9, 179–192, https://doi.org/10.1007/s13679-020-00379-w (2020) VallianouN. StratigouT. ChristodoulatosG.S. TsigalouC. DalamagaM. Probiotics, prebiotics, synbiotics, postbiotics, and obesity: current evidence, controversies, and perspectives Curr. Obes. Rep. 9 179 192 https://doi.org/10.1007/s13679-020-00379-w 2020 10.1007/s13679-020-00379-w32472285 Search in Google Scholar

47 Vandenplas Y., Huys G., Daube G.: Probiotics: an update. J. Pediatr. (Rio J.), 91, 6–21, doi: 10.1016/j.jped.2014.08.005. Epub 2014 Oct 23. (2015) VandenplasY. HuysG. DaubeG. Probiotics: an update J. Pediatr. (Rio J.) 91 6 21 10.1016/j.jped.2014.08.005 Epub 2014 Oct 23. 2015 25458874 Open DOISearch in Google Scholar

48 Wieërs G., Belkhir L., Enaud R., Leclercq S., Philippart de Foy J.M., Dequenne I., de Timary P., Cani P.D.: How probiotics affect the microbiota. Front. Cell Infect. Microbiol. 9, 454, doi:10.3389/fcimb.2019.00454 (2020) WieërsG. BelkhirL. EnaudR. LeclercqS. Philippart de FoyJ.M. DequenneI. de TimaryP. CaniP.D. How probiotics affect the microbiota Front. Cell Infect. Microbiol. 9 454 10.3389/fcimb.2019.00454 2020 697444132010640 Open DOISearch in Google Scholar

49 Wilkins L.J., Monga M., Miller A.W.: Defining dysbiosis for a cluster of chronic diseases. Sci. Rep. 9, 12918, doi:10.1038/s41598-019-49452-y (2019) WilkinsL.J. MongaM. MillerA.W. Defining dysbiosis for a cluster of chronic diseases Sci. Rep. 9 12918 10.1038/s41598-019-49452-y 2019 673386431501492 Open DOISearch in Google Scholar

50 Wu C., Huang J., Zhou R.: Genomics of lactic acid bacteria: current status and potential applications. Crit. Rev. Microbiol. 43, 393–404, doi: 10.1080/1040841X.2016.1179623 (2017) WuC. HuangJ. ZhouR. Genomics of lactic acid bacteria: current status and potential applications Crit. Rev. Microbiol. 43 393 404 10.1080/1040841X.2016.1179623 2017 28502225 Open DOISearch in Google Scholar

51 Yadav R., Kumar V., Baweja M., Shukla P.: Gene editing and genetic engineering approaches for advanced probiotics: a review. Crit. Rev. Food Sci. Nutr. 58, 1735–1746, doi: 10.1080/10408398.2016.1274877 (2018) YadavR. KumarV. BawejaM. ShuklaP. Gene editing and genetic engineering approaches for advanced probiotics: a review Crit. Rev. Food Sci. Nutr. 58 1735 1746 10.1080/10408398.2016.1274877 2018 28071925 Open DOISearch in Google Scholar

52 Yadav M., Shukla P.: Efficient engineered probiotics using synthetic biology approaches: a review. Biotechnol. Appl. Biochem. 67, 22–29, doi: 10.1002/bab.1822 (2020) YadavM. ShuklaP. Efficient engineered probiotics using synthetic biology approaches: a review Biotechnol. Appl. Biochem. 67 22 29 10.1002/bab.1822 2020 31538358 Open DOISearch in Google Scholar

53 Yadav M., Shukla P.: Recent systems biology approaches for probiotics use in health aspects: a review. 3 Biotech. 9, 448, doi: 10.1007/s13205-019-1980-5 (2019) YadavM. ShuklaP. Recent systems biology approaches for probiotics use in health aspects: a review 3 Biotech. 9 448 10.1007/s13205-019-1980-5 2019 684828731763126 Open DOISearch in Google Scholar

54 Yao M., Xie J., Du H., McClements D.J., Xiao H., Li L.: Progress in microencapsulation of probiotics: a review. Compr. Rev. Food Sci. Food Saf. 19, 2, 857–874, doi: 10.1111/1541-4337.12532 (2020) YaoM. XieJ. DuH. McClementsD.J. XiaoH. LiL. Progress in microencapsulation of probiotics: a review Compr. Rev. Food Sci. Food Saf. 19 2 857 874 10.1111/1541-4337.12532 2020 33325164 Open DOISearch in Google Scholar

55 Zhou Z., Chen X., Sheng H., Shen X., Sun X., Yan Y., Wang J., Yuan Q.: Engineering probiotics as living diagnostics and therapeutics for improving human health. Microb. Cell Fact. 19, 56, doi: 10.1186/s12934-020-01318-z (2020) ZhouZ. ChenX. ShengH. ShenX. SunX. YanY. WangJ. YuanQ. Engineering probiotics as living diagnostics and therapeutics for improving human health Microb. Cell Fact. 19 56 10.1186/s12934-020-01318-z 2020 705504732131831 Open DOISearch in Google Scholar

56 Zou Y., Chen T.: Engineered akkermansia muciniphila: a promising agent against diseases. Exp. Ther. Med. 20, 285, doi: 10.3892/etm.2020.9415 (2020) ZouY. ChenT. Engineered akkermansia muciniphila: a promising agent against diseases Exp. Ther. Med. 20 285 10.3892/etm.2020.9415 2020 766813033209129 Open DOISearch in Google Scholar

57 Zuo F., Chen S., Marcotte H.: Engineer probiotic bifidobacteria for food and biomedical applications – current status and future prospective. Review Biotechnol. Adv. 45, 107654, doi: 10.1016/j.biotechadv.2020.107654 (2020) ZuoF. ChenS. MarcotteH. Engineer probiotic bifidobacteria for food and biomedical applications – current status and future prospective Review Biotechnol. Adv. 45 107654, 10.1016/j.biotechadv.2020.107654 2020 33159984 Open DOISearch in Google Scholar